Navigation Links
Icagen Terminates Phase III ASSERT Study

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 - Icagen, Inc. (NASDAQ: ICGN) announced today that following a planned meeting of the independent Data Monitoring Committee ("DMC") of the Company's ASSERT trial of senicapoc (formerly ICA-17043) for the treatment of sickle cell disease in adults, the DMC recommended that the trial be terminated because of the low probability of achieving a reduction in crisis rate, the primary endpoint. In making their recommendation, the DMC noted that data from the trial indicated the expected increases in hemoglobin and hematocrit and decreases in reticulocytes as well as LDH and bilirubin, both markers of hemolysis. Among the available data, there were no statistically significant differences in safety measurements between the senicapoc and placebo treatment groups. The Company has informed the FDA of its plan to terminate the study based upon the DMC's recommendation. The Company will analyze final data when available and consider future options for the development of senicapoc.

About Icagen

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company's four most advanced programs are: -0-

 - senicapoc for sickle cell disease, which is discussed above.

    Senicapoc is being co-developed under an agreement with the McNeil

    Pediatrics Division of McNeil-PPC, Inc., a subsidiary of Johnson &

    Johnson.

-0-
 - lead compounds for epilepsy and neuropathic pain, for which the

    Company is conducting preclinical studies;

-0-
- a lead compound for atrial fibril
'"/>




Page: 1 2 3

Related medicine technology :

1. Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Icagen Terminates Phase III ASSERT Study
(Date:7/30/2015)... 30, 2015  EP Global Communications, Inc. (Public OTC: ... contacted the Company about discussing EPGL,s electronic contact ... Monday, August 3, 2015.  Novartis CEO Joe ... the coming electronic contact lens market could be ... next several years.  Novartis partnered with Google in ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex ... it will report its second quarter 2015 financial results ... a conference call and live webcast at 4:30 p.m. ... clinical development programs and a general corporate update. ... the Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... , July 30, 2015  Amgen (NASDAQ: AMGN ... partner and managing director of Warburg Pincus LLC, to the ... to welcome Fred Hassan and the deep, global ... Board," said Robert A. Bradway , chairman and chief ... to innovation will serve Amgen well." Mr. Hassan ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
(Date:7/30/2015)... , ... July 30, 2015 , ... Dale Sky Jones, ... States, will speak at the International Cannabis Professionals Expo held at the Caribe Royal ... The International Cannabis Professionals Expo is the largest medical cannabis expo in ...
(Date:7/30/2015)... ... 2015 , ... Committed to helping the next generation succeed - Mercy College ... to the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call ... the support they need to think more broadly about their future. Building on what ...
(Date:7/30/2015)... IL (PRWEB) , ... July 30, 2015 , ... ... according to results from the 2015 Most Wired Survey conducted by Hospitals & Health ... integrated health system owned and operated by The Sisters of the Third Order ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life ... the go. With no water needed, the refreshing berry-flavored tablets are the perfect ... get the natural ingredients that may help with body detoxification, protection and hydration,” ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine ... Meeting and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected ... vendors, will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual ...
Breaking Medicine News(10 mins):Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
... important nutrients for the development of healthy nerves and ... among seniors, reports a new epidemiological study. ... USDA HNRCA, "we found a strong relationship between high ... and older who also had adequate levels of vitamin ...
... Cold Spring Harbor Laboratory (CSHL) have solved a decades-old ... suppressor gene, but have revealed// a master switch for ... effective cancer therapy in the future," said CSHL Associate ... was published in the February issue of Cell. ...
... study undertaken by a group of Spanish scientists, amongst ... University of Navarra and the Centre for Applied Medical ... a new line of treatment for patients with acute ... have been published in the official journal, Blood, of ...
... decade ago, Tom Todaro was talking to researchers at the Fred ... slow down tumor// growth by slowing the rate at which tumor ... not exploit the reaction in reverse and get cells to grow ... that has come up with techniques for increasing crop yields with ...
... suggests that strep infections in children may increase involuntary ... ,In an eight-month study of 693 children ... researchers found that shortly after the number of strep ... rise in involuntary movements and disruptive behaviors — symptoms ...
... thousands of doctors of Indian origin in Britain - many ... and gurudwaras - after they lost a case Friday against ... gain employment in the country's National Health Service (NHS). ... the prospect of returning home, while others waiting to find ...
Cached Medicine News:Health News:Optimum Folate and Vitamin B12 Levels Essential for Cognitive Function in Seniors 2Health News:Scientists Discover New Gene 2Health News:A New Treatment Discovered For Acute Lymphoblastic Leukemia 2Health News:Cancer Research May Help Biofuels 2Health News:Strep, Psychiatric Symptoms Possibly Linked in Some Children 2Health News:Strep, Psychiatric Symptoms Possibly Linked in Some Children 3Health News:Indian Doctors in Britain Lose Legal Battle 2Health News:Indian Doctors in Britain Lose Legal Battle 3Health News:Indian Doctors in Britain Lose Legal Battle 4
... The Finnpipette Digital Multichannel, with ... lighter work of routine laboratory ... these advanced features: Soft-touch tip ... volume pipetting (0.5-10ul models), Entire ...
Inquire...
... And Impact2 Pipettors , , Available ... channel Impact and Impact2 pipettors can effectively ... with the same ergonomic design and superior ... are equally easy to program for a ...
... is ideal for all liquid handling applications ... operating buttons, and various dispensing techniques such ... make this a lab favorite. It intuitively ... pipette without any adverse effects on the ...
Medicine Products: